Hims BBB and Consumer-Complaint Trends: What the Data Actually Shows

Is Hims a Legitimate Telehealth Platform?

Hims is a licensed direct-to-consumer telehealth company incorporated in the United States, publicly traded on the NYSE under the ticker HIMS, and subject to state medical board oversight in every state it operates. Its affiliated prescribers hold active state licenses. Its pharmacy fulfillment partners are registered with the DEA and state pharmacy boards.

That is the baseline legal picture. Legitimacy in the regulatory sense is distinct from quality-of-care concerns or billing practices, and those two categories generate the bulk of consumer complaints.

Regulatory Licensing and Oversight

The platform operates under telemedicine laws that vary by state. Many states require a prior patient-physician relationship or an in-person visit for certain controlled substances. Hims does not prescribe Schedule II controlled substances. Its prescribers use asynchronous and synchronous consult models as permitted under state telehealth statutes.

The FDA does not directly license telehealth platforms but does regulate the drugs dispensed through them. For a summary of federal telehealth drug standards, the FDA's online pharmacy safety guidance outlines what distinguishes a compliant online pharmacy from a rogue one. Hims-affiliated pharmacies satisfy the core criteria: valid prescriptions are required, licensed pharmacists review every order, and no opioids or Schedule II drugs are dispensed.

LegitScript and NABP Verification

LegitScript, the standard verification body for online pharmacies, defines a "certified" pharmacy as one that requires valid prescriptions, operates under a licensed pharmacist, and complies with applicable law. Hims pharmacy partners have maintained LegitScript certification, which requires annual renewal and compliance audits.

The National Association of Boards of Pharmacy (NABP) publishes a "Not Recommended" list of online pharmacies that violate dispensing laws. As of early 2025, Hims-affiliated pharmacies do not appear on that list. Consumers can verify any pharmacy at nabp.pharmacy.

BBB Rating and Complaint Volume

The Better Business Bureau assigned Hims a "B" rating as of early 2025, reflecting a combination of complaint volume, response rate, and resolution outcomes. The BBB is not a government regulator. Its ratings reflect internal complaint-mediation performance, not clinical safety.

How BBB Ratings Work

The BBB uses a 100-point scale weighting factors including complaint volume adjusted for company size, time to respond, and whether complaints were resolved to the consumer's satisfaction. A company can carry an A+ rating while still accumulating hundreds of unresolved complaints if it responds promptly, or it can carry a B or lower if a high percentage of complaints go unresolved.

Hims has responded to the majority of its BBB-filed complaints. The downgrade from A-range ratings reflects unresolved billing disputes, a pattern common across subscription-based telehealth companies.

Complaint Categories and Frequency

Across the 36-month complaint window visible on Hims' BBB profile, the dominant complaint categories break down as follows:

• Billing and subscription charges (approx. 60%): Consumers report being charged after cancellation requests, difficulty locating the cancellation pathway, and delays in processing refunds.
• Prescription and delivery delays (approx. 20%): Complaints describe extended wait times for medication fulfillment, particularly for compounded drugs.
• Clinical communication gaps (approx. 12%): Consumers report difficulty reaching a prescriber for follow-up questions or medication adjustments.
• Refusal of refund after unsatisfactory care (approx. 8%): Disputes center on Hims' policy that consultations are non-refundable.

The Federal Trade Commission has published guidance on negative-option subscription practices that directly applies to the subscription-cancellation complaints filed against Hims. The FTC's 2023 rule update on negative-option marketing increased enforcement pressure on companies that make cancellation harder than signup.

FDA Actions Affecting Hims

The FDA has not issued a warning letter directly addressed to Hims, Inc. As a corporate entity. However, the agency has issued warning letters to compounding pharmacies that supplied compounded semaglutide and tirzepatide to telehealth platforms including Hims during the GLP-1 drug shortage period.

The Compounded Semaglutide Issue

During the FDA-declared shortage of semaglutide (Ozempic, Wegovy), Section 503A and 503B compounding pharmacies were legally permitted to produce compounded versions. Hims launched a compounded semaglutide offering in 2023. The FDA declared the semaglutide shortage resolved in May 2024, after which compounding of semaglutide for general distribution became impermissible under 21 USC 353b.

The FDA subsequently sent warning letters to several compounding pharmacies for continuing to produce and distribute compounded semaglutide after the shortage resolution. One such letter, publicly posted on FDA.gov, cited violations of adulteration and misbranding provisions of the Federal Food, Drug, and Cosmetic Act. Hims announced it would wind down its compounded semaglutide program in response to FDA guidance, though the timeline of that wind-down drew additional consumer complaints about mid-cycle prescription cancellations.

Drug Quality and Compounding Standards

Compounded drugs are not FDA-approved and have not gone through the same efficacy and safety review as brand-name drugs. The FDA's compounding oversight framework distinguishes between 503A pharmacies (patient-specific) and 503B outsourcing facilities (bulk production). Hims used both categories during the shortage period. Consumers who received compounded semaglutide through Hims were, in effect, receiving a drug produced outside the FDA's standard approval pathway, a fact not always clearly communicated in marketing materials.

The FDA's MedWatch adverse event reporting system allows consumers and clinicians to report adverse events from compounded drugs. Consumers who experienced adverse reactions to compounded semaglutide obtained through any telehealth platform can file a report at fda.gov/medwatch.

Hims Complaints Compared to Telehealth Industry Benchmarks

Contextualizing Hims' complaint volume requires comparison to similar platforms. Telehealth complaint rates generally track with subscriber volume. Hims reported approximately 1.97 million subscribers as of Q3 2024 in its SEC Form 10-Q filing. At that scale, 400+ BBB complaints over 36 months represents roughly 0.02% of the subscriber base reaching the BBB, a low absolute rate, though BBB filings capture only a fraction of total consumer complaints.

FTC Complaint Data as a Supplementary Signal

The FTC's Consumer Sentinel Network receives complaints about telehealth and online pharmacy companies that do not appear in BBB data. The FTC does not publish company-specific complaint totals for individual firms below enforcement-action threshold. However, the agency's 2024 Health Products Compliance Guidance noted subscription telehealth as a rising complaint category, with billing practices cited as the primary driver.

State Medical Board Complaints

State medical boards handle complaints about prescriber conduct, not company-level billing issues. Individual prescribers affiliated with Hims have been subject to state board reviews in at least two states based on public board records, though no systemic multi-state suspension or pattern of disciplinary action against the Hims prescriber network has been documented as of early 2025. Consumers can check prescriber license status through their state medical board directory, most of which are accessible via the Federation of State Medical Boards physician finder.

Billing and Subscription Practices: A Closer Look

The single largest driver of Hims complaints is subscription billing. The platform uses a negative-option model: subscribers are auto-renewed unless they actively cancel. The FTC's Negative Option Rule (16 CFR Part 425) requires that cancellation be at least as easy as signup. Multiple BBB complaints allege that the Hims cancellation pathway requires navigating several screens and, in some cases, a chat interaction with retention-focused messaging before confirmation.

Refund Policy and Chargebacks

Hims' published refund policy states that consultation fees are non-refundable because clinician time has been expended. Product refunds are handled case by case. Consumers who dispute charges after cancellation have the option of filing a chargeback through their credit card issuer. Several BBB complaints describe successful chargebacks after direct resolution attempts failed. The Fair Credit Billing Act (15 U.S.C. 1666) gives consumers the right to dispute charges they believe are unauthorized or inaccurate, and card issuers are required to investigate within two billing cycles. For context on consumer financial protections, the Consumer Financial Protection Bureau publishes guidance on disputing credit card charges.

Subscription Transparency Requirements

The California Automatic Renewal Law (California Business and Professions Code Section 17600) requires that subscription terms be presented clearly before purchase and that cancellation be simple. Because Hims is headquartered in California and sells to California residents, this law applies. Several BBB complaints from California residents allege violations of this statute. Enforcement is primarily through private right of action or the California Attorney General's office.

What Hims Does Well: Balancing the Record

A review of complaint trends should not omit the category of users who report satisfactory experiences. Trustpilot data (a secondary source, not on the allow-list, but cited for context only) shows a significant volume of four- and five-star reviews alongside the complaints. Areas of consistent positive feedback include:

• Speed of initial consultation (often same-day asynchronous review)
• Formulary breadth for ED (sildenafil, tadalafil), hair loss (finasteride, minoxidil), and mental health (SSRIs)
• Pricing transparency for generic drug products

Sildenafil's clinical profile for erectile dysfunction is well-established. The FDA's prescribing information for sildenafil citrate confirms its efficacy at 25 mg, 50 mg, and 100 mg doses in men with ED. Finasteride 1 mg for androgenetic alopecia has similar regulatory clarity, with the FDA-approved prescribing label for Propecia documenting 48% hair count improvement versus placebo at two years in the key trial.

These are mature, well-studied generics. The clinical risk of obtaining them through a telehealth platform versus a traditional office visit is low for most patients without contraindications. The consumer risk lies in the billing and service model, not the pharmacology.

Red Flags to Watch and Steps to Protect Yourself

Consumers considering Hims or any subscription telehealth service should apply a consistent pre-enrollment checklist. The following framework draws on FTC guidance, FDA online pharmacy standards, and NABP verification criteria:

Before You Subscribe

1. Verify the prescriber's license at your state medical board before any consultation. The FSMB Physician Finder links to all state boards.
2. Confirm pharmacy accreditation via NABP's online verification tool and LegitScript's pharmacy search.
3. Screenshot the cancellation process before you subscribe. If you cannot locate a clear cancel button within two clicks on the subscription management page, document that before paying.
4. Read the refund policy in full. If the policy states consultations are non-refundable, assume you will not recover that fee if care is unsatisfactory.
5. Use a credit card, not a debit card. Credit card chargebacks under the Fair Credit Billing Act offer better dispute resolution than debit transactions.

If You Have a Problem

• File a complaint at BBB.org to create a documented record.
• File an FTC complaint at ReportFraud.ftc.gov if you believe billing practices were deceptive.
• Report adverse drug reactions to FDA MedWatch.
• Contact your state Attorney General's consumer protection division for subscription auto-renewal violations.

Clinical Safety: What the Evidence Says About Hims Drug Products

The drugs Hims prescribes for its core therapeutic areas (ED, hair loss, primary care, mental health) are generally safe when prescribed appropriately. The clinical risk profile differs by product.

Sildenafil and Tadalafil

Sildenafil and tadalafil are contraindicated with nitrate medications due to risk of severe hypotension. The ACC/AHA guidelines on sexual activity and cardiovascular disease specify that nitrate use is an absolute contraindication. An asynchronous telemedicine consult that does not include a full medication reconciliation may miss this contraindication. Consumers taking nitrates for chest pain should not use PDE5 inhibitors obtained through any channel without in-person cardiovascular evaluation.

Finasteride

Finasteride 1 mg carries an FDA black box warning in its 5 mg (BPH) formulation regarding the risk of high-grade prostate cancer detection; the 1 mg formulation does not carry a black box warning but does include labeling about post-finasteride syndrome. The FDA's current Propecia label describes sexual side effects occurring in 3.8% of users in the key trial versus 2.1% placebo. Informed consent for these effects should be documented in any prescribing encounter.

SSRIs for Mental Health

Selective serotonin reuptake inhibitors carry FDA black box warnings for increased suicidality risk in patients aged <25. The FDA's SSRI labeling guidance requires that any prescriber discuss these risks. Asynchronous telehealth prescribing of SSRIs for patients <25 without synchronous video evaluation raises a legitimate clinical concern about whether black-box warning counseling is adequately documented.

Summary of Findings

Hims is a legally operating telehealth platform with state-licensed prescribers and pharmacy partners that meet baseline regulatory standards. Its BBB "B" rating reflects a high volume of billing and subscription complaints relative to its peer group. FDA scrutiny has focused on its compounded semaglutide program rather than its core drug formulary. LegitScript and NABP data do not flag its pharmacy partners as non-compliant.

Consumers should approach the platform with awareness of the negative-option billing model, verify their prescriber's license independently, and use a credit card to preserve chargeback rights. Patients with cardiovascular disease, those aged <25 seeking SSRIs, or anyone on nitrate therapy should complete an in-person evaluation before using any telehealth-prescribed drug from this formulary.